Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) in a research note issued to investors on Sunday. The brokerage set a "sell" rating on the biopharmaceutical company's stock.

Several other research firms have also recently issued reports on LXRX. HC Wainwright reaffirmed a "buy" rating and set a $4.00 price target on shares of Lexicon Pharmaceuticals in a research note on Friday, March 28th. Piper Sandler lowered their target price on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Leerink Partners reiterated a "market perform" rating and issued a $1.00 price target (down from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. Needham & Company LLC restated a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. Finally, Leerink Partnrs downgraded Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $3.67.

Remove Ads

Lexicon Pharmaceuticals Price Performance

Lexicon Pharmaceuticals stock traded down $0.01 during midday trading on Friday, reaching $0.50. The company's stock had a trading volume of 2,932,283 shares, compared to its average volume of 6,317,714. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45. Lexicon Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $2.45. The firm has a market capitalization of $122.48 million, a PE ratio of -0.66 and a beta of 1.02. The stock's 50 day simple moving average is $0.51 and its 200 day simple moving average is $0.89.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The firm had revenue of $26.55 million for the quarter, compared to the consensus estimate of $6.48 million. On average, equities research analysts forecast that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bayesian Capital Management LP purchased a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth about $31,000. RPO LLC purchased a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $33,000. Renaissance Technologies LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter valued at $38,000. Arizona State Retirement System boosted its position in Lexicon Pharmaceuticals by 34.4% during the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company's stock worth $47,000 after purchasing an additional 16,136 shares during the period. Finally, Teacher Retirement System of Texas raised its position in Lexicon Pharmaceuticals by 60.3% in the fourth quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company's stock valued at $48,000 after purchasing an additional 24,615 shares during the period. 74.70% of the stock is currently owned by institutional investors and hedge funds.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.